Amedisys, Inc. Expected to Earn FY2022 Earnings of $4.82 Per Share (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMEDGet Rating) – Analysts at Oppenheimer dropped their FY2022 EPS estimates for shares of Amedisys in a report issued on Thursday, January 19th. Oppenheimer analyst M. Wiederhorn now anticipates that the health services provider will post earnings of $4.82 per share for the year, down from their previous estimate of $4.86. Oppenheimer has a “Outperform” rating and a $125.00 price objective on the stock. The consensus estimate for Amedisys’ current full-year earnings is $4.84 per share. Oppenheimer also issued estimates for Amedisys’ Q4 2022 earnings at $0.98 EPS, FY2023 earnings at $4.75 EPS, Q2 2024 earnings at $1.31 EPS, Q3 2024 earnings at $1.28 EPS, Q4 2024 earnings at $1.29 EPS, FY2024 earnings at $4.99 EPS and FY2025 earnings at $5.46 EPS.

Several other research analysts have also weighed in on AMED. Benchmark lowered their price objective on shares of Amedisys from $165.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, October 3rd. SVB Leerink lowered their price objective on shares of Amedisys from $96.00 to $85.00 and set a “market perform” rating on the stock in a research note on Thursday, January 5th. Raymond James downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a report on Thursday, October 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $150.00 target price on shares of Amedisys in a report on Wednesday, November 2nd. Finally, Cowen reduced their target price on shares of Amedisys to $103.00 in a report on Friday, November 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amedisys currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.19.

Amedisys Stock Up 1.7 %

Amedisys stock opened at $95.47 on Friday. The firm has a market capitalization of $3.10 billion, a PE ratio of 25.73, a P/E/G ratio of 2.01 and a beta of 0.96. The company’s 50-day moving average is $86.16 and its 200-day moving average is $102.61. Amedisys has a fifty-two week low of $79.30 and a fifty-two week high of $179.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.06 and a quick ratio of 1.06.

Amedisys (NASDAQ:AMEDGet Rating) last released its quarterly earnings data on Wednesday, October 26th. The health services provider reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.24 by ($0.09). The firm had revenue of $557.99 million for the quarter, compared to analyst estimates of $579.30 million. Amedisys had a return on equity of 16.00% and a net margin of 5.45%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.53 earnings per share.

Hedge Funds Weigh In On Amedisys

Several hedge funds and other institutional investors have recently made changes to their positions in AMED. First Horizon Advisors Inc. raised its position in shares of Amedisys by 862.5% in the 2nd quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock valued at $40,000 after buying an additional 345 shares in the last quarter. Neo Ivy Capital Management acquired a new position in shares of Amedisys in the 2nd quarter valued at approximately $44,000. IFP Advisors Inc raised its position in shares of Amedisys by 331.1% in the 3rd quarter. IFP Advisors Inc now owns 569 shares of the health services provider’s stock valued at $47,000 after buying an additional 437 shares in the last quarter. Covestor Ltd raised its position in shares of Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after buying an additional 152 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Amedisys in the 1st quarter valued at approximately $68,000. 96.17% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.